LianBio Completes $325 Million US IPO to Support China In-Licensing Program
publication date: Nov 2, 2021
LianBio, a Princeton-Shanghai company, raised $325 million in its NASDAQ IPO at a market capitalization of $1.9 billion to support its drug in-licensings for China. LianBio was formed by Perceptive Advisors as a way for the US company to participate in China's market. It has access to the China rights for Perceptive's portfolio of life science companies, though it doesn't have a lock on those rights. Perceptive seeded the company originally, which then raised $310 million from outside investors soon after breaking out of stealth mode one year ago. More details....
Stock Symbol: (NSDQ: LIAN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.